Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan AN2 Therapeutics (ANTX)

AN2 Therapeutics (ANTX) - logo korporat

AN2 Therapeutics, Inc. (ANTX) relies on outsourcing the production and testing of molecules to minimize capital expenditures. The business faces intense pressure from global pharmaceutical behemoths in the pulmonary therapy segment. The firm's environmental footprint is limited to bio-waste disposal. The current EV/EBITDA ratio stands at 0.00, which is detailed in the price action chart provided below.

AN2 Therapeutics - Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan ANTX (periode 23.11.2025 - 16.11.2026)

Ringkesan rincian data analitis AN2 Bio (ANTX)

- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
Analisis umum perusahaan:AN2 Therapeutics Inc ANTX
Sampel barang AN2 Therapeutics Inc

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before taxes and amortization, allowing for the determination of an asset's fair price regardless of its financing structure. By analyzing the trend of the base EV/EBITDA multiple, an investor assesses the capitalization stability of AN2 Therapeutics, Inc. (ANTX) against the backdrop of patent protection for its drugs, where delays in clinical trials may temporarily distort the company's fundamental value.